219 related articles for article (PubMed ID: 30651598)
1. Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model.
Gunaratna RT; Santos A; Luo L; Nagi C; Lambertz I; Spier M; Conti CJ; Fuchs-Young RS
Oncogene; 2019 May; 38(18):3535-3550. PubMed ID: 30651598
[TBL] [Abstract][Full Text] [Related]
2. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
3. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice.
Li B; Rosen JM; McMenamin-Balano J; Muller WJ; Perkins AS
Mol Cell Biol; 1997 Jun; 17(6):3155-63. PubMed ID: 9154814
[TBL] [Abstract][Full Text] [Related]
4. P53 codon 72 polymorphism in Taiwanese breast cancer patients.
Chen FM; Ou-Yang F; Yang SF; Tsai EM; Hou MF
Kaohsiung J Med Sci; 2013 May; 29(5):259-64. PubMed ID: 23639512
[TBL] [Abstract][Full Text] [Related]
5. A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models.
Zhao Y; Wu L; Yue X; Zhang C; Wang J; Li J; Sun X; Zhu Y; Feng Z; Hu W
Elife; 2018 Mar; 7():. PubMed ID: 29557783
[TBL] [Abstract][Full Text] [Related]
6. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
7. The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation.
Kung CP; Liu Q; Murphy ME
Cancer Biol Ther; 2017 Jul; 18(7):484-491. PubMed ID: 28475405
[TBL] [Abstract][Full Text] [Related]
8. Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion.
Chatterjee G; Rosner A; Han Y; Zelazny ET; Li B; Cardiff RD; Perkins AS
Am J Pathol; 2002 Dec; 161(6):2241-53. PubMed ID: 12466138
[TBL] [Abstract][Full Text] [Related]
9. The Codon 72
Cho JH; Patel B; Bonala S; Mansouri H; Manne S; Vadrevu SK; Ghouse S; Kung CP; Murphy ME; Astrinidis A; Henske EP; Kwiatkowski DJ; Markiewski MM; Karbowniczek M
Mol Cancer Res; 2019 Aug; 17(8):1639-1651. PubMed ID: 31088907
[TBL] [Abstract][Full Text] [Related]
10. In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53.
Hosokawa Y; Papanikolaou A; Cardiff RD; Yoshimoto K; Bernstein M; Wang TC; Schmidt EV; Arnold A
Transgenic Res; 2001 Oct; 10(5):471-8. PubMed ID: 11708657
[TBL] [Abstract][Full Text] [Related]
11. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
14. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
15. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
16. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mouse models of breast cancer.
Regua AT; Arrigo A; Doheny D; Wong GL; Lo HW
Cancer Lett; 2021 Sep; 516():73-83. PubMed ID: 34090924
[TBL] [Abstract][Full Text] [Related]
18. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers.
Andrechek ER; Laing MA; Girgis-Gabardo AA; Siegel PM; Cardiff RD; Muller WJ
Cancer Res; 2003 Aug; 63(16):4920-6. PubMed ID: 12941816
[TBL] [Abstract][Full Text] [Related]
20. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes.
Kung CP; Khaku S; Jennis M; Zhou Y; Murphy ME
Mol Cancer Res; 2015 Feb; 13(2):250-62. PubMed ID: 25256710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
